53 annotations
Lana, a biosimilar to STELARA and Becenbia biosimilar to Soliris, are both expected to launch in the U.S. in Q1 of 2025
(No comment added)
Transcript
2024 Q2
9 Aug 24
I said we now expect CapEx of $1.3 billion in '24 versus the most recent guidance, which was $1.1 billion to $1.2 billion
(No comment added)
Transcript
2024 Q2
9 Aug 24
we have initiated activities to further expand MariTide manufacturing capacity
(No comment added)
Transcript
2024 Q2
9 Aug 24
the next obesity asset
(No comment added)
Transcript
2024 Q2
9 Aug 24
We're also pursuing oral medicines.
(No comment added)
Transcript
2024 Q2
9 Aug 24
weekly injectable products are probably more vulnerable to orals than a convenient monthly dosing
(No comment added)
Transcript
2024 Q2
9 Aug 24
this new study is not a gating step at all for the Phase III program for patients with obesity
(No comment added)
Transcript
2024 Q2
9 Aug 24
later this year, we will initiate an additional dedicated Phase II study that will characterize MariTide from the treatment of diabetes in patients with and without obesity
(No comment added)
Transcript
2024 Q2
9 Aug 24
We are expanding capacity in our state-of-the-art manufacturing facilities, including investments to support MariTide.
(No comment added)
Transcript
2024 Q2
8 Aug 24
We are actively planning and expect to initiate a broad Phase III program in obesity, obesity-related conditions and diabetes, along with a Phase II trial investigating MariTide for the treatment of diabetes in patients with and without obesity.
Beyond MariTide, we continue to progress our early obesity programs that consists of both oral and injectable incretin and non-accreting approaches.
(No comment added)
Transcript
2024 Q2
8 Aug 24
Enbrel sales decreased 15% year-over-year for the second quarter, primarily driven by lower net selling price.
(No comment added)
Transcript
2024 Q2
8 Aug 24
We are laser focused on preparing to launch a broad Phase III program for MariTide that includes obesity, obesity-related conditions and Type 2 diabetes, and we're further ramping our investment to support MariTide in the rest of the pipeline.
(No comment added)
Transcript
2024 Q2
8 Aug 24
by top line data from the ongoing MariTide Phase II study
(No comment added)
Transcript
2024 Q2
8 Aug 24
We look forward to additional data readouts later this year
(No comment added)
Transcript
2024 Q2
8 Aug 24
We remain on track and look forward to top line 52-week data from the ongoing MariTide Phase II study in late 2024.
(No comment added)
Transcript
2024 Q2
7 Aug 24
, monthly or as Murdo said, even less frequent dosing.
(No comment added)
Transcript
2024 Q2
7 Aug 24
It has 11 arms at test
(No comment added)
Transcript
2024 Q2
7 Aug 24
a 592 patient study
(No comment added)
Transcript
2024 Q2
7 Aug 24
Phase II study
(No comment added)
Transcript
2024 Q2
7 Aug 24
after just 3 doses, MariTide in that Phase I study, we saw persistent weight loss really out 150 days or more at some doses
(No comment added)
Transcript
2024 Q2
7 Aug 24